• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Med Virol . Clinical features and antibody response of patients from a COVID-19 treatment hospital in Wuhan, China

tetano

Editor, Senior Moderator
J Med Virol


. 2020 Oct 21.
doi: 10.1002/jmv.26617. Online ahead of print.
Clinical features and antibody response of patients from a COVID-19 treatment hospital in Wuhan, China


Yong Chen[SUP] 1 2 [/SUP], Yuehua Ke[SUP] 1 2 [/SUP], Xiong Liu[SUP] 1 2 [/SUP], Zhihua Wang[SUP] 1 3 [/SUP], Ruizhong Jia[SUP] 1 2 [/SUP], Wei Liu[SUP] 1 2 [/SUP], Chaojie Yang[SUP] 1 2 [/SUP], Leili Jia[SUP] 1 2 [/SUP], Yong Wang[SUP] 1 2 [/SUP], Li Han[SUP] 1 2 [/SUP], Xinyi Xia[SUP] 1 4 [/SUP], Sibing Zhang[SUP] 1 5 [/SUP], Changjun Wang[SUP] 1 2 [/SUP]



Affiliations

Abstract

Background: Coronavirus disease 2019 (COVID-19) has rapidly evolved into a global pandemic.
Methods: A total of 1578 patients admitted into a newly built hospital specialized for COVID-19 treatment in Wuhan, China, were enrolled. Clinical features and the levels of SARS-CoV-2 IgM and IgG were analyzed.
Results: In total, 1532 patients (97.2%) were identified as laboratory-confirmed cases. Seventy-seven patients were identified as asymptomatic carriers (n=64) or SARS-CoV-2 RNA positive before symptom onset (n=13). The positive rates of SARS-CoV-2 IgM and IgG were 80.4% and 96.8%, respectively. The median of IgM and IgG titers were 37.0 AU/mL (IQR: 13.4-81.1 AU/mL) and 156.9 AU/mL (IQR: 102.8-183.3 AU/mL), respectively. The IgM and IgG levels of asymptomatic patients (median titers, 8.3 AU/mL and 100.3 AU/mL) were much lower than those in symptomatic patients (median titers, 38.0 AU/mL and 158.2 AU/mL). A much lower of IgG level was observed in critical ill patients 42 to 60 days after symptom onset. There were 153 patients with viral RNA shedding after IgG detection. These patients had a higher proportion of critical illness during hospitalization (P<0.001) and a longer hospital stay (P<0.001) compared to patients with viral clearance after IgG detection. Coronary heart disease (OR, 1.89 [95% CI, 1.11-3.24], p=0.020), and ICU admission (OR, 2.47 [95% CI, 1.31-4.66], p=0.005) were independent risk factors associated with viral RNA shedding after IgG detection.
Conclusion: Symptomatic patients produced more antibodies than asymptomatic patients. The patients who had SARS-CoV-2 RNA shedding after developing IgG were more likely to be sicker patients. This article is protected by copyright. All rights reserved.

Keywords: COVID-19; Clinical features; Epidemiology; SARS-CoV-2 specific antibody; Viral shedding.
 
Back
Top Bottom